Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door

J Clin Oncol. 2016 Dec 20;34(36):4320-4322. doi: 10.1200/JCO.2016.68.2989. Epub 2016 Oct 31.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Approval / legislation & jurisprudence*
  • Drug Costs / legislation & jurisprudence*
  • Drug Industry / economics
  • Drug Industry / legislation & jurisprudence*
  • Government Regulation*
  • Health Services Accessibility / economics
  • Health Services Accessibility / legislation & jurisprudence*
  • Humans
  • Medical Indigency / legislation & jurisprudence
  • Medically Uninsured / legislation & jurisprudence
  • Orphan Drug Production / economics
  • Orphan Drug Production / legislation & jurisprudence*
  • Policy Making
  • United States
  • United States Dept. of Health and Human Services / legislation & jurisprudence*
  • United States Food and Drug Administration / legislation & jurisprudence*